MedBulletinsAura Celeste
Rheumatology

Monthly rheumatology bulletin — November 18, 2026

🎧 Listen to this issueAudio newscast · 6:21 min

Colleagues: this issue covers October 19 to November 18, 2026. The month was dominated by ACR Convergence 2026 (Orlando, November 6–11), with many phase 2 and 3 results that are still conference abstracts without peer review, so we read them with caution; when a presentation repeats results reported before this period, we say so and give the date. There were also three relevant regulatory decisions and the APLAR 2026 congress in Seoul (October 28 to November 1).

1. Rheumatoid arthritis and spondyloarthritis

1. Ixekizumab plus tirzepatide in psoriatic arthritis with overweight or obesity

[Clinical trial] [United States / multinational]

TOGETHER-PsA, a 52-week, randomized, open-label, assessor-blinded phase 3b trial in 271 adults with psoriatic arthritis and overweight or obesity: ixekizumab (anti-IL-17A) combined with tirzepatide achieved week-52 ACR50 in 43.7% versus 15.7% with ixekizumab alone. According to Lilly, the week-52 analyses are pre-specified exploratory objectives without multiplicity control; the primary endpoint was assessed at week 36. Lilly reported on November 11 that these 52-week results were presented at ACR Convergence 2026 and simultaneously published in Arthritis & Rheumatology.

Why it matters: it treats obesity as a target within the psoriatic arthritis strategy, highly relevant to everyday practice; but it is an open-label Lilly trial (Lilly owns both drugs), and the week-52 data are exploratory. Local applicability will depend on cost and coverage.

Sources

2. FDA approves tildrakizumab for active psoriatic arthritis

[Regulatory FDA] [United States / India]

Sun Pharma announced on October 30 FDA approval of tildrakizumab (anti-IL-23p19), already approved for plaque psoriasis, for adults with active psoriatic arthritis. Approval rests on the phase 3 INSPIRE-1 and INSPIRE-2 trials (52-week, randomized, double-blind, placebo-controlled), which showed superiority in week-24 ACR20; neither the release nor the coverage reports the figures. The dose is 100 mg subcutaneously, administered by a healthcare provider at weeks 0 and 4 and every 12 weeks thereafter.

Why it matters: it adds another quarterly-dosed IL-23 inhibitor to a crowded class; without published trial figures or head-to-head data, there is no reason to prefer it over guselkumab or risankizumab until the full data are available.

Sources

3. Oral icotrokinra in biologic-naive psoriatic arthritis

[Congress] [United States / multinational]

ICONIC-PsA 1, a phase 3, randomized, double-blind, placebo-controlled trial in 552 biologic-naive adults: the oral IL-23 receptor-targeted peptide at 200 mg daily achieved week-16 ACR20 in 58% versus 41% with placebo, a significant difference according to Johnson & Johnson (November 7); the 400 mg dose (52%) was not significantly different from placebo, according to coverage. At week 24, with 200 mg: ACR20 69%, ACR50 40% and ACR70 18% (no placebo comparison). It was presented as a late-breaking poster at ACR Convergence (LB12).

Why it matters: oral IL-23 pathway blockade would be an alternative to injections, but the fact that the higher dose was not significantly different from placebo means waiting for ICONIC-PsA 2 and full publication; in the US the drug is approved only for plaque psoriasis.

Sources

2. Lupus, vasculitis and inflammatory myopathies

4. Secukinumab for polymyalgia rheumatica: approved in the European Union and the United States

[Regulatory EMA/FDA] [European Union / United States]

Novartis announced European Commission approval on October 21 and FDA approval on November 17 (150 mg dose, in adults with an inadequate response to corticosteroids or who cannot tolerate a corticosteroid taper); according to Novartis, it is the first and only anti-IL-17 biologic approved for polymyalgia rheumatica. In REPLENISH (phase 3, randomized, double-blind, 381 patients with recent relapse), published in NEJM, sustained remission at week 52 was 40.6% with 150 mg and 41.2% with 300 mg versus 20.4% with placebo (p<0.001), with a lower adjusted annual cumulative glucocorticoid dose (1683 mg with 150 mg vs 2093 mg with placebo). According to the approval information, serious adverse events were similar (15.9% vs 14.2%), with more hypersensitivity (14% vs 9%) and urinary tract infections (13% vs 7%).

Why it matters: it is a steroid-sparing option for relapsing patients, but six in ten treated patients did not achieve sustained remission and the prednisone saving is modest (about 400 mg per year). Local applicability will depend on cost and coverage.

Sources

5. Obinutuzumab in lupus nephritis: histologic remission and intrarenal B-cell depletion

[Congress] [United States / multinational]

Subgroup analysis of the REGENCY trial with week-76 biopsies (32 patients on obinutuzumab plus standard therapy and 32 on placebo). ACR Convergence presented these exploratory REGENCY analyses again on November 9 (abstract 1823); the same results had been reported at the Pediatric Rheumatology Symposium on March 19, 2026, so they are not new results from this period. Histologic remission was more frequent with obinutuzumab and, among patients without complete renal response, 52.6% (10 of 19) reached an NIH activity index of 0 versus 8.3% (2 of 24) with placebo. B-cell depletion in renal parenchyma was greater (adjusted difference in change in B-cell count: -16.6; p<0.0001; subgroup of 14 and 15 patients).

Why it matters: it suggests that clinical response underestimates the tissue effect and supports the role of repeat biopsy, but it is a subgroup analysis, in small groups, and presented by an investigator with ties to the manufacturer; on its own it does not change practice.

Sources

6. CAR-T therapy in refractory lupus: pooled analysis of 243 patients

[Meta-analysis] [United States]

A systematic review and pooled analysis from the Hospital for Special Surgery, presented at ACR Convergence: 31 studies, 243 patients with systemic lupus erythematosus who had tried at least two immunosuppressants, most treated with autologous anti-CD19 CAR-T cells. Mean SLEDAI fell from 13.0 to 2.2 at six months; cytokine release syndrome occurred in 64% of participants (61% of all participants had grade 1 or 2 cytokine release syndrome), neurotoxicity in 5%, grade 3 or 4 infections in 5% and hematologic toxicity lasting more than 28 days in 6%.

Why it matters: the efficacy signal is consistent, but it comes from small uncontrolled series with likely publication bias; it remains a therapy for specialized centers and clinical trials.

Sources

7. Ianalumab in Sjögren's disease: two phase 3 trials in NEJM

[Clinical trial] [Multinational]

NEPTUNUS-1 (275 patients) and NEPTUNUS-2 (504 patients), randomized, double-blind, 52-week trials of ianalumab (anti-BAFF-R) 300 mg subcutaneously monthly versus placebo (NEPTUNUS-2 also included a 300 mg every-three-months arm), published in NEJM on October 21: ESSDAI at week 48 improved by 1.3 and 1 point more than placebo, both statistically significant; in NEPTUNUS-2, only the monthly regimen outperformed placebo. No statistically significant differences versus placebo were detected in ESSDAI response of 5 points or more (NEPTUNUS-1) or in patient-reported symptoms measured with ESSPRI (in both trials). Serious events were similar, with more injection-related reactions.

Why it matters: formally positive, but the authors themselves describe the effect as small, and no statistically significant differences were detected in patient-reported symptoms, which matter most to patients; trials funded by Novartis.

Sources

8. Afimetoran, an oral TLR7/8 inhibitor, in active lupus

[Congress] [Multinational]

A randomized, double-blind, placebo-controlled, dose-finding phase 2 trial in 248 patients with active systemic lupus erythematosus, presented as a late-breaking abstract (LB23) on November 11: week-48 SRI-4 response was 64.1% to 67.8% across the three doses (2.5, 10 and 30 mg daily) versus 34.4% with placebo (p<0.001), with serious adverse events in 5.9% versus 12.9%.

Why it matters: an oral drug with a new target and a difference of about 30 points is a strong signal, but this is a manufacturer's phase 2 trial and confirmatory phase 3 data are lacking.

Sources

3. Gout, osteoarthritis and osteoporosis

9. Pozdeutinurad, a URAT1 inhibitor, in gout: phase 3 REDUCE-2

[Congress] [Multinational]

A randomized, double-blind, placebo-controlled phase 3 trial in 811 patients with uncontrolled gout. Sobi had announced the primary result on May 21: at six months, serum urate below 6 mg/dL was reached by 69.2% with 75 mg, 56.6% with 50 mg and 8.1% with placebo (p<0.0001). The detailed data, with the effect sustained through 12 months, were released on October 29 as an ACR Convergence late-breaking abstract. Treatment-emergent adverse events were similar across groups (60.7% to 61.7% with pozdeutinurad and 60.9% with placebo).

Why it matters: a potent uricosuric that could help patients who do not tolerate allopurinol or do not reach target, but the comparator was placebo rather than allopurinol or febuxostat, flares, tophi and detailed renal safety are not reported in the released data, and the data come from Sobi.

Sources

10. Retatrutide in knee osteoarthritis with obesity: TRIUMPH-4

[Clinical trial] [United States / multinational]

A 68-week randomized, double-blind, placebo-controlled phase 3 trial in 445 adults without diabetes with knee osteoarthritis pain and mean BMI of 40.4, published in NEJM on November 8 and presented at ACR Convergence (abstract 0871). In the primary pain analysis (hybrid estimand), WOMAC pain fell by 3.96 points with weekly retatrutide 9 mg and 3.74 with 12 mg versus 2.12 with placebo (differences of -1.83 and -1.61; p<0.001). Weight fell by 20.0% and 23.7% versus 4.6% with placebo (treatment-regimen estimand; p<0.001). There were two deaths in the active arms, judged unrelated, and gastrointestinal events predominated. The publication also includes the TRIUMPH-1-OA trial.

Why it matters: it supports the idea that intensive weight loss relieves osteoarthritis pain, but improvement with placebo was considerable and the drug is not approved; the trial was funded by Lilly, which was involved in its design and analysis.

Sources

4. Biologic and targeted therapies, biosimilars

11. China approves its first golimumab biosimilar

[Regulatory NMPA] [China]

Bio-Thera Solutions (Guangzhou) announced on November 5 that China's National Medical Products Administration (NMPA) approved its golimumab biosimilar, Ashuli, for rheumatoid arthritis and ankylosing spondylitis; according to the company, it is the first golimumab biosimilar approved in China. The announcement does not include equivalence trial data. (source in Chinese)

Why it matters: monthly anti-TNF biosimilars can lower access costs, including in Latin American markets, where the company has commercialization agreements; but without the comparative trial in the announcement we cannot assess equivalence here.

Sources

12. Olokizumab in refractory rheumatoid arthritis: Russian data at APLAR 2026

[Congress] [Russia / South Korea]

At APLAR 2026 (Seoul), at a symposium sponsored by R-Pharm, a retrospective analysis was presented of 3624 patients with rheumatoid arthritis treated with olokizumab (anti-IL-6) for at least one year: of the 113 with difficult-to-treat disease, 52% reached low disease activity or remission at six months and 61% at one year, and the proportion of patients on glucocorticoids was halved. (source in Russian)

Why it matters: a retrospective, uncontrolled study presented at a manufacturer's symposium, with data from Russia only; it serves as real-world data, not as evidence of comparative efficacy.

Sources

Cross-cutting

13. A large language model speeds up rheumatology diagnosis without demonstrating greater accuracy

[Clinical trial] [Germany]

ALLIANCE, a randomized, open-label, multicenter trial of 82 physicians from seven hospitals (21 rheumatologists and 61 non-rheumatologists) who worked through clinical vignettes of Cogan syndrome, dermatomyositis and familial Mediterranean fever: top-one diagnostic accuracy rose from 22.2% to 33.3% with LLM support and from 23.3% to 35% with conventional resources; the model did not demonstrate a statistically significant accuracy benefit over conventional resources (adjusted OR 0.99; 95% CI 0.45 to 2.19). Time per case was 94 seconds with the model versus 206 seconds with conventional resources, and overconfidence was observed in all settings and increased after the intervention. ACR Convergence presented ALLIANCE on November 11 (abstract 2950, by an investigator from Marburg University Hospital); its results were already available in a non-peer-reviewed preprint posted on September 2, 2026.

Why it matters: a randomized AI trial in the specialty with a useful message: it saves time but does not replace clinical reasoning; these were simulated cases, not real patients.

Sources

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.